Perioperative Effects of Radiological Contrast Agents

Classification of Contrast Agents

Radiological contrast agents fall into three main categories based on their chemical composition and clinical application:

Iodinated Contrast Media

Iodinated agents contain iodine atoms that absorb X-rays, creating radiographic contrast. These are classified by:

Osmolality:

• High-osmolar contrast media (HOCM): 1500-2000 mOsm/kg (approximately 5-8 times plasma osmolality of 285-295 mOsm/kg)
• Low-osmolar contrast media (LOCM): 600-800 mOsm/kg (approximately 2-3 times plasma osmolality)
• Iso-osmolar contrast media (IOCM): 290 mOsm/kg (equivalent to plasma)

Ionic structure:

• Ionic monomers (HOCM): diatrizoate, iothalamate
• Non-ionic monomers (LOCM): iopamidol, iohexol, iopromide
• Non-ionic dimers (IOCM): iodixanol

The trend toward LOCM and IOCM has significantly reduced adverse effects, though complications still occur.

Gadolinium-Based Agents

Used primarily for MRI, gadolinium chelates include:

• Linear chelates: gadopentetate dimeglumine, gadobenate dimeglumine
• Macrocyclic chelates: gadoterate meglumine, gadobutrol

Macrocyclic agents are more stable with lower risk of gadolinium dissociation.

Barium Sulphate

An inert suspension used for gastrointestinal imaging. Though generally safe when contained within the GI tract, extravasation or aspiration carries significant risks.

Cardiovascular Effects

Haemodynamic Changes

Iodinated contrast media produce predictable cardiovascular effects through multiple mechanisms:

Direct myocardial depression:

• Negative inotropic effect through calcium channel interference
• More pronounced with HOCM than LOCM/IOCM
• Clinically significant in patients with ejection fraction <30%
• Transient reduction in systolic function lasting 10-20 minutes

Peripheral vasodilation:

• Immediate vasodilation following injection
• Mediated by endothelial nitric oxide release
• Transient hypotension (typically 10-20 mmHg systolic decrease)
• Compensatory tachycardia (10-20 bpm increase)
• More pronounced with HOCM due to higher osmolality

Volume effects:

• Osmotic load draws fluid into intravascular space
• Can precipitate pulmonary oedema in patients with limited cardiac reserve
• Volume expansion of approximately 10-15% occurs within minutes
• Risk particularly elevated when contrast volume exceeds 2-3 mL/kg

Arrhythmias

Electrocardiographic changes occur in 10-30% of patients receiving iodinated contrast:

• Sinus bradycardia (most common, vagally mediated)
• Ventricular ectopy
• Transient QT prolongation
• Rarely, ventricular tachycardia or fibrillation
• Risk factors include pre-existing cardiac disease and rapid bolus injection

Coronary Effects

Selective coronary angiography presents specific risks:

• Direct endothelial injury
• Coronary vasospasm (particularly with HOCM)
• Transient ST-segment changes in 5-10% of procedures
• Contrast-induced myocardial stunning

Renal Effects

Contrast-Induced Acute Kidney Injury (CI-AKI)

Defined as serum creatinine increase ≥44 μmol/L or ≥25% from baseline within 48-72 hours of contrast administration.

Pathophysiology involves:

• Direct tubular toxicity from reactive oxygen species
• Medullary hypoxia from altered renal haemodynamics
• Vasoconstriction of medullary vessels
• Tubular obstruction from contrast precipitation (especially with dehydration)

Incidence:

• General population: 1-2%
• Chronic kidney disease (eGFR <60): 10-20%
• Diabetes plus CKD: 20-30%
• Multiple risk factors: up to 50%

Risk factors include:

• Pre-existing renal impairment (most significant)
• Diabetes mellitus
• Dehydration
• Contrast volume >1.5 mL/kg or >300 mL total
• Multiple contrast studies within 72 hours
• Concurrent nephrotoxins (NSAIDs, aminoglycosides, ACE inhibitors)
• Heart failure
• Advanced age (>75 years)
• Anaemia
• Hypotension during procedure

Prevention strategies:

• Adequate hydration (isotonic saline 1 mL/kg/hr for 12 hours pre- and post-procedure)
• Minimizing contrast volume (use volume-to-creatinine clearance ratio <3)
• Withholding nephrotoxic medications
• Using iso-osmolar or low-osmolar agents
• Avoiding diuretics perioperatively
• Consider sodium bicarbonate infusion in high-risk patients (150 mL/hr for 6 hours)

N-acetylcysteine (600-1200 mg twice daily) remains controversial with conflicting evidence.

Hypersensitivity and Anaphylactoid Reactions

Classification of Reactions

Acute reactions (within 1 hour):

Mild (70-95% of reactions):

• Urticaria, pruritus
• Nausea, vomiting
• Flushing
• Metallic taste

Moderate (3-5%):

• Bronchospasm
• Facial oedema
• Vasovagal reactions
• Hypotension requiring treatment

Severe (<0.1%):

• Anaphylaxis
• Laryngeal oedema
• Cardiovascular collapse
• Loss of consciousness
• Seizures

Mechanisms

Most reactions are anaphylactoid (non-IgE mediated):

• Direct mast cell and basophil degranulation
• Complement activation
• Contact system activation
• Dose-independent
• Can occur on first exposure

True IgE-mediated anaphylaxis is rare but can occur with repeated exposures.

Risk Factors

• Previous reaction to contrast (strongest predictor: 17-35% recurrence risk)
• Asthma (5-fold increased risk)
• Allergy history
• Beta-blocker therapy (may mask symptoms and reduce epinephrine response)
• Mastocytosis
• Female gender
• Cardiovascular disease

Prophylaxis for High-Risk Patients

Standard regimen:

• Prednisolone 50 mg orally 13 hours, 7 hours, and 1 hour before procedure
• Plus antihistamine (H1 blocker: promethazine 25 mg or equivalent) 1 hour before
• Consider addition of H2 blocker (ranitidine 50 mg IV)

Alternative emergency protocol (when premedication not possible):

• Hydrocortisone 200 mg IV immediately
• Antihistamine IV
• Delay procedure 4-6 hours if feasible

Thyroid Effects

Iodine Load

Standard contrast CT delivers 15,000-30,000 μg of iodine (normal daily requirement 150 μg):

• Transient suppression of thyroid hormone synthesis (Wolff-Chaikoff effect)
• Usually resolves within weeks
• Risk of thyrotoxicosis in susceptible patients

Contrast-Induced Thyrotoxicosis

Occurs in patients with:

• Autonomous nodules
• Graves' disease in remission
• Iodine deficiency (paradoxically)
• Elderly patients in iodine-deficient regions

Manifestations:

• Onset typically 2-12 weeks post-exposure
• Atrial fibrillation
• Weight loss
• Tremor, anxiety
• Heart failure

Prevention:

• Screen high-risk patients (TSH measurement)
• Consider prophylactic thionamides in very high-risk patients
• Post-procedure monitoring in susceptible individuals

Neurological Effects

Contrast-Induced Encephalopathy

Rare complication characterized by:

• Confusion, altered consciousness
• Seizures (focal or generalized)
• Focal neurological deficits
• Cortical blindness
• Usually resolves within 24-72 hours

Risk factors:

• Disrupted blood-brain barrier (recent stroke, infection, hypertension)
• Renal impairment
• High contrast doses
• Intra-arterial cerebral injection

Mechanism:

• Blood-brain barrier disruption
• Direct neurotoxicity
• Osmotic effects causing oedema

Gadolinium Deposition

Recent recognition of gadolinium accumulation in:

• Deep brain nuclei (globus pallidus, dentate nucleus)
• Particularly with linear chelates
• Clinical significance uncertain
• No proven neurotoxicity in patients with normal renal function

Pulmonary Effects

Acute Pulmonary Reactions

Non-cardiogenic pulmonary oedema:

• Rare (<0.1%)
• Mechanism: increased capillary permeability
• Onset within minutes to hours
• Presents as acute respiratory distress

Bronchospasm:

• More common in asthmatics (4-8% vs 0.5% general population)
• Mediated by histamine and leukotriene release
• Usually occurs within 5 minutes
• Treat as acute asthma: bronchodilators, oxygen, steroids if severe

Aspiration of Barium

Catastrophic if barium enters airways:

• Chemical pneumonitis
• Acute respiratory distress syndrome
• Hypoxaemic respiratory failure
• Management: immediate bronchoscopy, supportive care
• High mortality (up to 50%)

Nephrogenic Systemic Fibrosis (NSF)

Rare but serious complication specific to gadolinium-based contrast in renal failure:

Risk factors:

• Severe renal impairment (eGFR <30 mL/min/1.73m²)
• Acute kidney injury
• Pro-inflammatory states
• Linear gadolinium chelates (greatest risk)

Clinical features:

• Progressive cutaneous fibrosis
• Joint contractures
• Scleroderma-like changes
• Internal organ fibrosis (heart, lungs, diaphragm)
• No effective treatment

Prevention:

• Avoid gadolinium if eGFR <30 unless absolutely necessary
• Use macrocyclic agents if required
• Consider haemodialysis immediately post-procedure (though efficacy uncertain)

Extravasation Injuries

Occurs in 0.1-0.9% of power injector administrations:

Manifestations:

• Local pain, swelling
• Skin blistering (with large volumes)
• Compartment syndrome (rare)
• Tissue necrosis (very rare, typically volumes >100 mL)

Management:

• Stop injection immediately
• Elevate affected limb
• Cold compresses for first 24 hours
• Surgical consultation if compartment syndrome suspected
• Most resolve spontaneously within days

Metformin Interaction

Metformin requires special consideration:

Traditional approach (now revised):

• Previous recommendation: withhold metformin for 48 hours post-contrast
• Rationale: fear of lactic acidosis if CI-AKI develops

Current evidence-based approach:

• Patients with eGFR ≥60: continue metformin
• Patients with eGFR 45-59: continue metformin, check creatinine 48 hours post-procedure
• Patients with eGFR 30-44: withhold metformin at time of procedure, check creatinine at 48 hours before restarting
• Patients with eGFR <30: contraindicated for contrast and metformin

Clinical Relevance

Preoperative Assessment

Anaesthetists must identify high-risk patients requiring:

• Alternative imaging modalities (ultrasound, non-contrast MRI)
• Prophylactic measures for allergic reactions
• Enhanced renal protective strategies
• Modification of perioperative medications

Risk stratification should include:

• Baseline renal function (measure eGFR)
• Previous contrast reactions
• Cardiac function assessment
• Volume status evaluation
• Medication review (nephrotoxins, metformin, beta-blockers)

Intraoperative Considerations

During procedures with contrast administration:

• Ensure adequate IV access separate from contrast injection site
• Maintain euvolaemia (guided by clinical assessment or monitoring)
• Monitor for acute reactions (anaphylaxis, bronchospasm)
• Have resuscitation drugs immediately available (epinephrine, bronchodilators)
• Consider invasive monitoring in high-risk cardiac patients
• Anticipate transient haemodynamic changes

Postoperative Monitoring

Implement appropriate surveillance:

• Serial renal function monitoring (baseline, 24-48 hours)
• Fluid balance documentation
• Recognition of delayed hypersensitivity reactions (up to 1 week)
• Assessment for volume overload in at-risk patients
• Neurological assessment if cerebral contrast used

Emergency Procedures

When contrast studies are urgent and cannot be delayed:

• Accept increased risk when benefits outweigh
• Implement maximum renal protection (hydration)
• Abbreviated allergic prophylaxis if history of reactions
• Prepare for management of complications
• Consider lower contrast volumes even if image quality compromised

Understanding these perioperative effects enables anaesthetists to optimize patient safety through risk stratification, preventive strategies, and prepared management of complications.